Phase IV Trial Terminated: Machine Learning-Guided Hydroxyurea Resistance Prediction in Polycythemia Vera — Clinical Implications for Haematologists

References

1. 1.Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., ... & Kiladjian, J. J. (2018). Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 32(5), 1057-1069. https://doi.org/10.1038/s41375-018-0077-1
2. 2.Barosi, G., Mesa, R., Finazzi, G., Harrison, C., Kiladjian, J. J., Lengfelder, E., ... & Barbui, T. (2013). Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 121(23), 4778-4781. https://doi.org/10.1182/blood-2013-01-478891
3. 3.ClinicalTrials.gov. (2024). HU-F-AIM - A Prospective, Interventional Study to Evaluate HU-resistance in Polycythemia Vera Patients Who Meet Predictive Parameters Identified in the Machine Learning Project PV-AIM. https://clinicaltrials.gov/study/NCT05853458
4. 4.Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., ... & Zuo, Z. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia, 36(7), 1703-1719. https://doi.org/10.1038/s41375-022-01613-1
5. 5.Tefferi, A. (2021). Polycythemia vera: 2021 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 96(4), 444-467. https://doi.org/10.1002/ajh.26063
6. 6.Verstovsek, S., Vannucchi, A. M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., ... & Kiladjian, J. J. (2017). Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 102(12), 2056-2065. https://doi.org/10.3324/haematol.2016.153098